OR-NIKE
5.2.2020 20:02:11 CET | Business Wire | Press release
Today, NIKE, Inc. (NYSE: NKE), unveiled breakthrough innovation for athletes competing in the Tokyo 2020 Games, including footwear designed to provide runners with a measurable performance benefit for a new era of competition. The NEXT% platform, introduced by barrier-breaking marathoner Eliud Kipchoge, will now expand into new disciplines following its unparalleled success in distance running.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200205005708/en/
Ahead of the hottest Games on record, Nike also debuted progressive new collections featuring sustainable materials for all athletes. As the growing climate emergency continues to disrupt competition and training, Nike’s sustainable innovations signal the brand’s commitment to helping protect the future of the planet – and, consequently, the future of sport. Highlights include our most sustainably designed medal stand uniform in Team USA history, footwear built predominantly from recycled waste and lifestyle apparel that embraces the goal of a zero-carbon future.
“At Nike, we see sport’s greatest stage as our biggest opportunity to show the world what’s possible,” said NIKE, Inc. President and CEO John Donahoe. “After all, what’s at stake isn’t just records, but the future of sport itself. In Tokyo, we’ll help the world’s best reach new levels of performance with our revolutionary platform, while sharing real solutions for the barriers all athletes face under rapidly changing climate conditions.”
- Team USA Medal Stand Collection [link ] : This summer, Team USA will prove the power of sustainability during medal ceremonies. In Tokyo, U.S. medalists will take the podium in iconic Windrunner jackets reengineered with 100% recycled polyester, pants featuring 100% recycled nylon and recycled-rubber Nike Grind trim and the Nike Air VaporMax 2020, constructed with recycled manufacturing material and precision-knit uppers for minimal waste.
- Nike Air Zoom Alphafly NEXT% [link ] : Call it the ultimate test run: when Eliud Kipchoge broke the two-hour marathon barrier in Vienna this past October, he was wearing a prototype of the Nike Air Zoom Alphafly NEXT%. In Summer 2020, Nike’s newest race-day shoe makes its official debut with two new Nike Air Zoom pods, additional foam, an updated carbon fiber plate and an ultra-breathable upper – all adding up to improved cushioning and running economy.
- Nike Air Zoom BB NXT [link ]: Nike Basketball's new Air Zoom BB NXT is engineered to be as light and responsive as possible. With a new Nike Air Zoom pod system, exposed Nike React foam and a thin plate positioned above the foam, the shoe provides athletes with lightweight strength, optimized impact protection and outstanding energy return.
- Nike SB Skateboarding Kits [link ] : For skateboarding’s debut on this summer’s global stage, Nike SB will introduce kits on the forefront of sustainable design. Athletes representing Team USA, France and Brazil will compete in uniforms designed with 100% recycled polyester, pattern efficiency for minimal waste and bright, bold styling (crafted in collaboration with Dutch artist Parra) to celebrate each nation’s unique sport culture.
- Space Hippie [link ] : In addition to product developed for athletes participating in the Tokyo 2020 Games, Nike will launch this spring an exploratory footwear collection that redefines what’s possible with sustainable product design. Space Hippie is constructed by transforming scrap material from factory floors – what Nike’s design teams have called “space junk” – into a radical expression of circular design. Every detail of the Space Hippie capsule collection, from material choices to methods of make to packaging, was chosen with consideration for its environmental impact, adding up to Nike’s lowest carbon footprint footwear.
NIKE, Inc., based near Beaverton, Oregon, is the world’s leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available on the Internet at http://investors.nike.com . Individuals can also visit http://news.nike.com and follow @NIKE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005708/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom